Detection of DNA hypermethylation in remote media of patients with colorectal cancer: New biomarkers for colorectal carcinoma

Tumor Biology

Volumn 33, Issue 2, 2012, Pages 297-305

  Herbst, Andreas ^a   Kolligs, Frank T ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biomarker; Blood; Colorectal cancer; DNA hypermethylation; Stool

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; NEUROGENIN 1; PROTEIN MLH1; SECRETED FRIZZLED RELATED PROTEIN 2; TRANSCRIPTION FACTOR GATA 4; DNA; TUMOR MARKER;

ARISTALESS LIKE HOMEOBOX GENE 4; ARTICLE; BLOOD ANALYSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CDKN2A GENE; COLORECTAL CANCER; DIAGNOSTIC VALUE; DNA METHYLATION; FECES ANALYSIS; GATA4 GENE; HMLH1 GENE; HUMAN; MARKER GENE; N MYC DOWNSTREAM REGULATED GENE 4; NEUROG1 GENE; OCCULT BLOOD; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SFRP2 GENE; TMEFF2 GENE; BIOLOGICAL MODEL; BLOOD; CHROMOSOME; COLORECTAL TUMOR; CPG ISLAND; FECES; GENETICS; METHODOLOGY; ONCOLOGY; PROGNOSIS; TIME; TUMOR SUPPRESSOR GENE;

CHROMOSOMES; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA; DNA METHYLATION; FECES; GENES, TUMOR SUPPRESSOR; HUMANS; MEDICAL ONCOLOGY; MODELS, GENETIC; PROGNOSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860313256     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0346-y     Document Type: Article

References (67)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Kinzler KW,Vogelstein B. Lessons fromhereditary colorectal cancer. Cell. 1996;87(2):159-70.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-67.
4. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, et al. Allelotype of colorectal carcinomas. Science. 1989;244(4901):207-11.
5. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415-28.
6. Rainier S, Johnson LA, Dobry CJ, PingAJ,Grundy PE, Feinberg AP. Relaxation of imprinted genes in human cancer. Nature. 1993;362 (6422):747-9.
7. Reik W, Surani MA. Cancer genetics. Genomic imprinting and embryonal tumours. Nature. 1989;338:112-3.
8. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science. 2003;299 (5613):1753-5.
9. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003;3(4):253-66.
10. Hiltunen MO, Alhonen L, Koistinaho J, Myöhänen S, Pääkkönen M, Marin S, et al. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma. Int J Cancer. 1997;70(6):644-8.
11. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995;55(20):4525-30.
12. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, et al. Methylation of the 5' CpG island of the p16/ CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995;55 (20):4531-5.
13. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998;95(12):6870-5.
14. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61(8):3225-9.
15. Smith-Ravin J, England J, Talbot IC, BodmerW. Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients. Gut. 1995;36(1):81-6.
16. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646-50.
17. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989;46(5):318-22.
18. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997;57 (5):808-11.
19. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994;7(4):536-40.
20. Lind GE, Danielsen SA, Ahlquist T, Merok MA, Andresen K, Skotheim RI, et al. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Canc. 2011;10:85.
21. Cui T, Chen Y, Yang L, Knösel T, Zöller K, Huber O, et al. DSC3 expression is regulated by p53, and methylation of DSC3 DNA is a prognostic marker in human colorectal cancer. Br J Cancer. 2011;104(6):1013-9.
22. Yi JM, Dhir M, Guzzetta AA, Iacobuzio-Donahue CA, Heo K, Yang KM, et al. DNA methylation biomarker candidates for early detection of colon cancer. Tumour Biol. 2012. doi:10.1007/ s13277-011-0302-2.
23. Lee S, Oh T, Chung H, Rha S, Kim C, Moon Y, et al. Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer. Int J Oncol. 2012;40(3):889-98.
24. Hellebrekers DMEI, LentjesMHFM, van den Bosch SM,Melotte V, Wouters KAD, Daenen KLJ, et al. GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res. 2009;15(12):3990-7.
25. Rawson JB, Mrkonjic M, Daftary D, Dicks E, Buchanan DD, Younghusband HB, et al. Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation in two large populations of colorectal cancer patients. Br J Cancer. 2011;104(12):1906-12.
26. Lind GE, Raiborg C, Danielsen SA, Rognum TO, Thiis-Evensen E, Hoff G, et al. SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis. Oncogene. 2011;30(37):3967-78.
27. Nakayama H, Hibi K, TaguchiM, Takase T, Yamazaki T, Kasai Y, et al. Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients. Cancer Lett. 2002;188(1-2):115-9.
28. Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 2001;61(3):900-2.
29. LeungWK, To K-F,Man EPS, ChanMWY, Bai AHC, Hui AJ, et al. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol. 2005;100(10):2274-9.
30. Lecomte T, Berger A, Zinzindohoué F, Micard S, Landi B, Blons H, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer. 2002;100(5):542-8.
31. Zou H-Z, Yu B-M, Wang Z-W, Sun J-Y, Cang H, Gao F, et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin Cancer Res. 2002;8(1):188-91.
32. Ebert MPA, Model F, Mooney S, Hale K, Lograsso J, Tonnes- Priddy L, et al. Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology. 2006;131(5):1418-30.
33. Tänzer M, Balluff B, Distler J, Hale K, Leodolter A, Röcken C, et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One. 2010;5(2): e9061.
34. Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, Schuster M, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem. 2008;54(2):414-23.
35. He Q, Chen H-Y, Bai E-Q, Luo Y-X, Fu R-J, He Y-S, et al. Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer. Canc Genet Cytogenet. 2010;202(1):1-10.
36. Lee BB, Lee EJ, Jung EH, Chun H-K, Chang DK, Song SY, et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res. 2009;15(19):6185-91.
37. Tang D, Liu J,Wang D-R, Yu H-F, Li Y-K, Zhang J-Q. Diagnostic and prognostic value of the methylation status of secreted frizzled-related protein 2 in colorectal cancer. Clin Invest Med. 2011;34(2):E88-95.
38. Herbst A, Rahmig K, Stieber P, Philipp A, Jung A, Ofner A, et al. Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer. Am J Gastroenterol. 2011;106 (6):1110-8.
39. Li M, Chen W-D, Papadopoulos N, Goodman SN, Bjerregaard NC, Laurberg S, et al. Sensitive digital quantification ofDNAmethylation in clinical samples. Nat Biotechnol. 2009;27(9):858-63.
40. Nakayama H, Hibi K, Takase T, Yamazaki T, Kasai Y, Ito K, et al. Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. Int J Cancer. 2003;105:491-3.
41. WallnerM, Herbst A, Behrens A, Crispin A, Stieber P, Göke B, et al. Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res. 2006;12(24):7347-52.
42. Herbst A,WallnerM, Rahmig K, Stieber P, Crispin A, Lamerz R, et al. Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence. Eur J Gastroenterol Hepatol. 2009;21(5):565-9.
43. MüllerHM,OberwalderM, FieglH, MorandellM,Goebel G, ZittM, et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet. 2004;363(9417):1283-5.
44. Lenhard K, Bommer GT, Asutay S, Schauer R, Brabletz T, Göke B, et al. Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol. 2005;3 (2):142-9.
45. Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, et al. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res. 2005;11(3):1203-9.
46. Chen W-D, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Canc Inst. 2005;97(15):1124-32.
47. Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC, Sontag S, et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. 2007;5(1):111-7.
48. Huang Z-H, Li L-H, Yang F, Wang J-F. Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol. 2007;13(6):950-4.
49. LeungWK, To K-F, Man EPS, ChanMWY, Hui AJ, Ng SSM, et al. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenterol. 2007;102(5):1070-6.
50. Chang E, Park DI, Kim YJ, Kim BK, Park JH, Kim HJ, et al. Detection of colorectal neoplasm using promoter methylation of ITGA4, SFRP2, and p16 in stool samples: a preliminary report in Korean patients. Hepatogastroenterology. 2010;57(101):720-7.
51. Wang D-R, Tang D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol. 2008;14(4):524-31.
52. Nagasaka T, Tanaka N, Cullings HM, Sun D-S, Sasamoto H, Uchida T, et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Canc Inst. 2009;101(18):1244-58.
53. ZhangW, Bauer M, Croner RS, Pelz JOW, Lodygin D, Hermeking H, et al. DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene. Dis Colon Rectum. 2007;50 (10):1618-26. discussion 1626-7.
54. Mayor R, Casadomé L, Azuara D, Moreno V, Clark SJ, Capellá G, et al. Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease. Br J Cancer. 2009;100(10):1534-9.
55. Glöckner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 2009;69(11):4691-9.
56. Zhang J, Yang S, Xie Y, Chen X, Zhao Y, He D, et al. Detection of methylated tissue factor pathway inhibitor 2 and human long DNA in fecal samples of patients with colorectal cancer in China. Canc Epidemiol. 2012;36(1):73-7.
57. Melotte V, Lentjes MHFM, van den Bosch SM, Hellebrekers DMEI, de Hoon JPJ,Wouters KAD, et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Canc Inst. 2009;101(13):916-27.
58. Ausch C,Kim Y-H, Tsuchiya KD, Dzieciatkowski S,Washington MK, Paraskeva C, et al. Comparative analysis of PCR-based biomarker assay methods for colorectal polyp detection from fecal DNA. Clin Chem. 2009;55(8):1559-63.
59. KimMS, Louwagie J, Carvalho B, Terhaar Sive Droste JS, Park HL, Chae YK, et al. PromoterDNAmethylation of oncostatinmreceptorbeta as a novel diagnostic and therapeutic marker in colon cancer. PLoS One. 2009;4(8):e6555.
60. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV, Laird PW. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res. 1999;59(10):2302-6.
61. Esteller M, Sanchez-CespedesM, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999;59(1):67-70.
62. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000;28(8): E32.
63. Hibi K, Goto T, Shirahata A, Saito M, Kigawa G, Nemoto H, et al. Detection of TFPI2 methylation in the serum of colorectal cancer patients. Cancer Lett. 2011;311(1):96-100.
64. Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Canc Epidemiol Biomarkers Prev. 2007;16(10):1935-53.
65. Devos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem. 2009;55(7):1337-46.
66. Lindforss U, Fredholm H, Papadogiannakis N, Gad A, Zetterquist H, Olivecrona H. Allelic loss is heterogeneous throughout the tumor in colorectal carcinoma. Cancer. 2000;88(12):2661-7.
67. Liu W, Guan M, Su B, Li J, Ma W, Liu C, et al. Rapid determination of AKAP12 promoter methylation levels in peripheral blood using methylation-sensitive high resolution melting (MS-HRM) analysis: application in colorectal cancer. Clin Chim Acta. 2010;411(13-14):940-6.